Timing of Tocilizumab Administration Under the Guidance of IL-6 in CAR-T Therapy for R/R Acute Lymphoblastic Leukemia
Authors:
Open Access
- 21 June 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 914959
Abstract
Chimeric antigen receptor T (CAR-T) cells targeting CD19 have achieved great clinical responses in patients with relapsed or refractory (R/R) acute B lymphoblastic leukemia. However, severe adverse events such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome restrict it to further application. Tocilizumab is the corner stone for the treatment of severe CRS. It has been used to treat mild CRS in recent years, whereas some statistical supports clarifying the suitable timing of its administration are lacking. Sixty-seven patients with B-cell acute lymphoblastic leukemia (B-ALL) were treated with CD19-CART and enrolled in the study, of which 33 patients received Tocilizumab. Application of Tocilizumab in patients with grade 2 CRS in American Society for Transplantation and Cellular Therapy (ASTCT) criteria can significantly shorten the duration of CRS without affecting side effects and long-term efficacy. However, a number of patients still developed severe CRS with early use of Tocilizumab, indicating the significance of the introduction of clinical laboratories to assist medications. Statistically, patients with less than fourfold increase in IL-6 levels had a higher incidence of severe CRS after receiving Tocilizumab (37.5% versus. 0%, p=0.0125), which provided a basis for refining CRS intervention strategies under the guidance of IL-6. Clinical Trial Registration: www.clinicaltrials.gov, NCT02965092 and NCT04008251Keywords
This publication has 29 references indexed in Scilit:
- Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic LeukemiaCancer Discovery, 2018
- Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cellsNature Medicine, 2018
- FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release SyndromeThe Oncologist, 2018
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic LeukemiaNew England Journal of Medicine, 2018
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 2018
- Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T CellsCancer Discovery, 2017
- Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adultsBlood, 2017
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trialThe Lancet, 2015
- Chimeric Antigen Receptor T Cells for Sustained Remissions in LeukemiaNew England Journal of Medicine, 2014
- Current concepts in the diagnosis and management of cytokine release syndromeBlood, 2014